Gastro-oesophageal Reflux Disease Trial, Recruiting (NCT05976165)

Gastro-oesophageal Reflux Disease Trial, Recruiting NCT05976165 Sponsor: Mayo Clinic Condition: Gastro-oesophageal Reflux Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05976165 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Gord

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People whose main symptoms are heartburn or acid coming back up into the throat (gastroesophageal reflux disease symptoms)
People who are able to understand and sign a consent form agreeing to take part in the trial

Who may not be able to join:

People who have previously been diagnosed with a condition called small intestinal bacterial overgrowth (SIBO), which is an excess of bacteria in the small intestine
People who have used certain acid-reducing medications (called PPIs or H2 blockers) in the past 3 months
People who have a serious ongoing illness affecting the kidneys, liver, joints, heart, or who have been diagnosed with cancer
People who have taken antibiotics within the past month
People who have had surgery on the oesophagus, stomach, or any part of the bowel
People who have been diagnosed with irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD)
People who are currently pregnant or breastfeeding
People who are planning to become pregnant
People who are unable to take a type of acid-reducing medication called PPIs, including those with an allergy or sensitivity to them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05976165

Sponsor: Mayo Clinic

Phase: Not Applicable

Status: Recruiting

Condition: Gastro-oesophageal Reflux Disease

More information: https://clinicaltrials.gov/study/NCT05976165

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People whose main symptoms are heartburn or acid coming back up into the throat (gastroesophageal reflux disease symptoms)
People who are able to understand and sign a consent form agreeing to take part in the trial

Who may not be able to join:

People who have previously been diagnosed with a condition called small intestinal bacterial overgrowth (SIBO), which is an excess of bacteria in the small intestine
People who have used certain acid-reducing medications (called PPIs or H2 blockers) in the past 3 months
People who have a serious ongoing illness affecting the kidneys, liver, joints, heart, or who have been diagnosed with cancer
People who have taken antibiotics within the past month
People who have had surgery on the oesophagus, stomach, or any part of the bowel
People who have been diagnosed with irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD)
People who are currently pregnant or breastfeeding
People who are planning to become pregnant
People who are unable to take a type of acid-reducing medication called PPIs, including those with an allergy or sensitivity to them

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

17 November 2023

Est. completion

1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of SIBO after treatment with PPI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov